A panel of experts review clinical scenarios and discuss treatment options for patients with chronic graft versus host disease.
EP. 1: Graft versus Host Disease Background
A panel of experts discusses the types of graft versus host disease and the biologic pathways that are thought to be involved.
EP. 2: Overview of GVHD Risk Factors
Catherine Lee explains risk factors that may contribute to the likelihood of a patient developing graft versus host disease.
EP. 3: Current GVHD Prophylaxis Strategies
Yi-Bin Chen leads the panel in a review of various GVHD prophylaxis regimens.
EP. 4: Signs and Symptoms of Acute and Chronic GVHD
Colleen Danielson, NP shares the signs and symptoms she commonly sees in patients with graft versus host disease.
EP. 5: Statistics on the Incidence of Chronic GVHD
Dr Chen presents statistics on the incidence of chronic graft versus host disease.
EP. 6: Identification of Patients at High Risk for GVHD
The panelists share their insights on the identification of patients at high risk for GVHD.
EP. 7: Assessment of Chronic GVHD Symptoms
Colleen Danielson, NP, walks through how chronic GVHD symptoms are assessed.
EP. 8: The NIH Clinical Scoring of Organ Systems
Corey Cutler details the NIH Clinical Scoring of Organ System for chronic GHVD symptoms.
EP. 9: The Chronic GVHD Treatment Paradigm
Dr Lee shares an overview of therapy and supportive care options for chronic GVHD according to the severity of a symptom.
EP. 10: Patient Case: A 48-Year-Old Man with Chronic GVHD
Dr Chen and Dr Cutler review a clinical case and discuss GVHD assessment for the patient.
EP. 11: Treatment Goals for a Patient With Chronic GVHD
The group discusses treatment goals and patient education for chronic GVHD.
EP. 12: Steroid-Refractory Chronic GVHD Background
The categories of steroid refractory gvhd are discussed: intolerant, unresponsive, and dependent.
EP. 13: Therapy Options for Steroid-Refractory Chronic GVHD
Experts in the treatment of graft versus host disease evaluate second-line agents for patients with steroid-refractory disease.
EP. 14: Ibrutinib as Second-Line Therapy for Steroid-Refractory Chronic GVHD
Catherine Lee reviews data on use of ibrutinib for steroid-refractory chronic graft versus host disease.
EP. 15: The iNTEGRATE Trial: Ibrutinib With Prednisone as First-Line Therapy for cGVHD
The panel discusses the iNTERGRATE trial of ibrutinib in combination with prednisone as frontline therapy for chronic GVHD.
EP. 16: The REACH3 Clinical Trial of Ruxolitinib in Chronic GVHD
Yi-Bin Chen reviews data from the REACH3 trial of ruxolitinib in patients with chronic steroid-refractory graft versus host disease.
EP. 17: Clinical Experience with Ruxolitinib for cGVHD
Experienced hematologist-oncologists offer their clinical experiences with ruxolitinib.
EP. 18: The ROCKstar Study of Belumosudil in cGVHD
Corey Cutler explains the ROCKstar clinical trial of belumosudil for steroid-refractory chronic GVHD.
EP. 19: Real-World Experience with Belumosudil
Clinical experiences with belusmosudil are shared among the panel.
EP. 20: Summary of Axatilimab for cGVHD
The clinical trial of a novel agent, axatilimab, is reviewed and analyzed.
EP. 21: Discussion of Long-Term Effects of GVHD Therapy
Chronic GVHD specialists share commentary on long-term effects of graft versus host disease and therapies for the condition.
EP. 22: Future Directions in Graft Versus Host Disease
Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.
2 Clarke Drive Cranbury, NJ 08512